ITIH4 and HIV infectious disease: Congruent with reports that promoter identity may augment the therapeutic efficacy of the CAR T cell product (37), MSCV- and MND-regulated anti-HIV duoCAR T cells displayed sustained anti-HIV activity, as evidenced by our demonstration of their ability to repeatedly eliminate HIV gp120–expressing cells in vitro (modeled using Env+ GFP+ target cells) and suppress productive HIV infection in vivo without signs of premature CAR T cell exhaustion or lack of persistence.